To test this idea, LIHC immunotherapy data of HCC were obtained through the TCIA database, and we compared the effect of PD-1 and CTLA-4 treatment between the high-risk and low-risk groups. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.